Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ANXIOLYTIC ‐ BUSPIRONE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether HERB ‐ GINKGO BILOBA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether POLYPEPTIDE ‐ CERULETIDE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 35 (mean) years old patients with schizophrenia and tardive dyskinesia, acute extrapyramidal symptoms, and/or…
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
HORMONE ‐ MELATONIN showed no clear difference in tardive dyskinesia: No clinically important improvement compared with PLACEBO OR NO TREATMENT (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
HORMONE ‐ MELATONIN showed no clear difference in tardive dyskinesia: Deterioration of symptoms compared with PLACEBO OR NO TREATMENT (low certainty).
1 finding from 1 review
Adverse effects · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia
ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
ANXIOLYTIC ‐ BUSPIRONE may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…
ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) probably leads to lower tardive dyskinesia: 1. No clinically important improvement compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects ‐ any adverse effect · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…
ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) showed no clear difference in adverse effects ‐ any adverse effect compared with PLACEBO (low certainty).
1 finding from 1 review